| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/157488707780599393 |
| P698 | PubMed publication ID | 18473997 |
| P50 | author | Christine A Pratilas | Q102380741 |
| P2093 | author name string | David B Solit | |
| P433 | issue | 2 | |
| P304 | page(s) | 121-134 | |
| P577 | publication date | 2007-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Reviews on recent clinical trials | Q27020351 |
| P1476 | title | Therapeutic strategies for targeting BRAF in human cancer | |
| P478 | volume | 2 |
| Q37639582 | A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors |
| Q33541323 | A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes |
| Q36216904 | Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients |
| Q34525316 | An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmolog |
| Q41765541 | B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger |
| Q92988012 | BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors |
| Q37988572 | BRAFmutation testing in clinical practice |
| Q36162685 | Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo |
| Q35020439 | Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK |
| Q34181861 | Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice |
| Q31132555 | Development and validation of a clinical trial patient stratification assay that interrogates 27 mutation sites in MAPK pathway genes |
| Q33917755 | Enabling individualized therapy through nanotechnology |
| Q33695315 | High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors |
| Q30419559 | In silico analysis of Single Nucleotide Polymorphisms (SNPs) in human BRAF gene |
| Q33607387 | Pediatric low-grade gliomas and the need for new options for therapy: Why and how? |
| Q42176497 | Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q36582552 | The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer |
| Q39490125 | Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status |
| Q45921946 | [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. |
Search more.